

## LETTERS TO THE EDITOR

### Successful treatment of recalcitrant condyloma with topical cidofovir

EDITOR,—Despite the high prevalence of condylomata acuminata, their treatment remains unsatisfactory for both patients and physicians. Epidemiological studies estimated the prevalence of genital warts between 1–31% with a peak occurring in young adults.<sup>1</sup> As a consequence, the economic burden of human papillomavirus (HPV) infection in the United States is estimated to exceed \$8.5 billion per year.<sup>2</sup> Current treatments rely on the ablation of warts (cryotherapy, laser vaporisation, electrodissection, or trichloroacetic acid) or the interruption of cell division (podophylox, intralesional or systemic interferon, and 5-fluorouracil). Recently, imiquimod has been successfully used as a topical immune response modifier for the treatment of external anogenital warts.<sup>3</sup> However, there remains a substantial number of patients who fail to respond to traditional and newer drugs. We report on such a patient with recalcitrant condylomata acuminata on the glans and shaft of the penis who was successfully treated using the novel antiviral cidofovir as a 1.5% gel.

A 48 year old man with a 2½ year history of condylomata acuminata had received laser treatment, podophylox, and imiquimod. The patient's history was remarkable for diabetes mellitus. He presented with numerous, flesh coloured, flat topped papules in a circular manner on the outer prepuce and the glans, whereas some lesions in the coronary sulcus had a more verruciform appearance (fig 1). On histological analysis, the typical picture of acanthosis, papillomatosis, and numerous koilocytes was seen. Papillomavirus typing revealed HPV-43 by nested PCR using consensus primers.<sup>4</sup>

Cidofovir was evaluated in the indicator patient at 1.5% cidofovir in a viscous gel (propylene glycol, parabene). Initially, the patient was treated on an outpatient basis with two applications of cidofovir gel per week to the respective lesions without any side effects. Thereafter, the patient was instructed to apply the gel three times a week by self application. At week 6 the patient pre-

sented with small erosions surrounded by a marked erythema on all treated sites (fig 1). The lesions were painful. Condylomata were still present in the coronary sulcus. At this point treatment was stopped and antiseptic treatment was given with betadine solution once daily. Seven weeks later (week 13) all lesions had completely healed (fig 1). Neither scarring nor dysaesthesia were noted. No recurrence has occurred since. Cidofovir, 1-[(S)-3-hydroxy-2-(phosphono-methoxy)-propyl]cytosine, is a member of a new class of antiviral agents (phosphonylether nucleotide analogues).<sup>5</sup> It shows potent in vitro activity against a broad spectrum of herpesviruses, including human cytomegalovirus (CMV), HSV-1 and HSV-2, and adenovirus.<sup>6</sup> Recent in vitro and in vivo studies have demonstrated activity against papillomavirus and poxvirus.<sup>6,7</sup>

Cidofovir is a nucleotide analogue of deoxycytidine monophosphate (dCMP). Analogous to the metabolism of dCMP to dCTP, cidofovir is converted to the active cidofovir diphosphate that inhibits viral DNA polymerases.<sup>8</sup> The uptake of cidofovir into cells is slow, but the intracellular half life of the various metabolites is between 6 and 87 hours, thus allowing infrequent dosing.<sup>8</sup> Compared with the general mechanism of activation of ganciclovir, which requires phosphorylation by the virus encoded UL97 gene, cidofovir does not depend on viral infection for its phosphorylation and can therefore prime cells to an antiviral state (prophylaxis).

The metabolism of cidofovir is negligible, since the majority (>80%) is recovered unchanged in the urine. The principal systemic toxicity (nephrotoxicity) can be avoided by topical application.

This initial case report suggests that topical cidofovir may represent a valuable addition to the armamentarium of hard to treat condyloma. However, a careful evaluation of the dose and frequency of cidofovir application is warranted.

U R HENGGE

Department of Dermatology and Venereology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany

G TIETZE

Hospital Pharmacy, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany

Correspondence to: U R Hengge  
dermatology@uni-essen.de

1 Koutsky L. Epidemiology of genital human papillomavirus infection. *Am J Med* 1997; 102:3–8.

- 2 Beutner KR, Reitman MV, Richwald GA, *et al* and the AMA Expert Panel on External Genital Warts. External genital warts: report of the American Medical Association Consensus Conference. *Clin Infect Dis* 1998;27:796–806.
- 3 Beutner KR, Spruance SL, Hougham AJ, *et al*. Treatment of genital warts with an immune-response modifier (imiquimod). *J Am Acad Dermatol* 1998;38:230–9.
- 4 Meyer T, Arndt R, Stockfleth E, *et al*. Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe. *Biotechniques* 1995;19:632–9.
- 5 De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. *Intervirology* 1997;40:295–303.
- 6 Snoeck R, Van Ranst M, Andrei G, *et al*. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. *N Engl J Med* 1995;333:943–4.
- 7 Meadows KP, Tyring SK, Pavia AT, *et al*. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. *Arch Dermatol* 1997;133:987–90.
- 8 Ho HT, Woods KL, Bronson JJ, *et al*. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy (phosphonylmethoxy)propyl]cytosine. *Mol Pharmacol* 1992;41:197–202.

Accepted for publication 11 January 2000

### Bladder carcinoma presenting to genitourinary medicine departments

EDITOR,—Large numbers of patients are seen in departments of genitourinary medicine with symptoms suggesting infection or inflammation of the genitourinary tract. Although bladder neoplasms typically cause painless haematuria, in a subgroup of patients they cause other urinary symptoms that may produce diagnostic confusion. We identified five patients who were referred to the genitourinary medicine service, and who were found to have bladder carcinoma (see table 1). Four of the patients presented to the genitourinary medicine department at High Wycombe (5500 new attendances per annum) between 1991 and 1998; the fifth patient presented to the Oxford genitourinary medicine department (9000 new attendances per annum) in 1997. None of the patients had an occupational history that placed them at higher risk for bladder cancer.

Men with bladder carcinoma typically present in later life (median age 69 years), but the condition may occur at younger ages.<sup>1</sup> A subgroup of patients develop frequency, urgency, and dysuria—symptoms usually associated with bladder infection.<sup>2</sup> Rarely, penile and perineal pain mimicking prostatitis may be a presenting feature, as in patients 3 and 4, who have been described in more detail elsewhere.<sup>3</sup>

Non-specific urethritis (NSU) is diagnosed commonly in genitourinary medicine clinics in men of all ages. In this series, patient 2 was referred with presumed NSU, and patient 4 had attended previously with a diagnosis of NSU, 2 years before the bladder cancer was diagnosed (at that time there were 5–10 white cells/high power field (×1000) on a urethral smear, and a chlamydia ELISA test and cultures for *Neisseria gonorrhoeae* were negative; no haematuria was detected). Both patients were subsequently noted to have neoplastic infiltration in the bladder neck area and prostatic urethra.

In all five cases a degree of persistent microscopic haematuria was noted at presentation; in patient 4 this was never greater than a trace on dipstick testing. Patient 1 reported intermittent painless macroscopic haematuria at presentation; he was referred by his general practitioner with suspected



Figure 1 Condylomata acuminata with some lesions in the coronary sulcus having a more verruciform appearance.

Table 1 Patient details

Patient No	Age (years)	Smoker	Referral source	Referral diagnosis	Presenting features	Urine dipstick	Urine cytology	Diagnosis and treatment
1	26	NR	GP	?Infection	3 months intermittent painless haematuria	Blood +ve (trace)	ND	Well differentiated bladder papillary TCC; non-invasive; resected
2	34	Yes	GP	?Urethritis	6 weeks frequency, dysuria	Blood +ve	ND	Poorly differentiated adenocarcinoma; bladder calculus also present; tumour resection, chemotherapy, and radiotherapy
3	53	No	GP	Recurrent prostatitis	1 year penile and suprapubic pain; frequency, dysuria	Blood +ve	Malignant	Extensive transitional cell carcinoma in situ, involving prostatic urethra; cystoprostatectomy
4	42	No	GP	Sterile pyuria ?cause	1 year penile and perineal pain, frequency, dysuria	Blood +ve (trace)	Malignant	Extensive TCC plus carcinoma in situ, involving prostatic urethra; cystoprostatectomy
5	50	Yes	GP	?Infection	6 weeks frequency, urgency, dysuria	Blood +ve	Suspicious	Poorly differentiated TCC at bladder neck; muscle invasion; cystoprostatectomy, and chemotherapy

NR = not recorded; ND = not done; TCC = transitional cell carcinoma.

genitourinary infection, rather than suspected neoplasia, because of his young age (26 years).

Bladder neoplasia is especially liable to cause irritative symptoms when represented by, or associated with, carcinoma in situ of the bladder urothelium.<sup>1,2</sup> Urine cytology may be useful in this subgroup, and was abnormal in all three of the five patients in whom it was requested. When this process involves the prostatic urethra, symptoms mimicking prostatitis may arise. Early diagnosis of bladder neoplasia is of prognostic importance; the presence of carcinoma in situ or prostatic involvement by bladder carcinoma are poor prognostic features for which radical surgery may be required.<sup>1,4</sup>

These cases highlight the importance of careful follow up of patients presenting with persistent irritative-type bladder symptoms, especially in an older age group, when specific tests for genitourinary infection are negative, and where microscopic haematuria is a feature. Bladder carcinoma should be considered in this subgroup; urine cytology and referral for cystourethroscopy may be indicated. Although rare in younger adult males, bladder cancer should not be ruled out in men under the age of 45 years, and our experience strengthens the case for continuing with routine urine testing in genitourinary medicine clinics.

G A LUZZI

South Buckinghamshire NHS Trust, Wycombe Hospital, High Wycombe, HP11 2TT and Oxford Radcliffe NHS Trust, Radcliffe Infirmary, Oxford OX2 6HE

A EDWARDS

Oxford Radcliffe NHS Trust, Radcliffe Infirmary, Oxford OX2 6HE

Correspondence to: Dr Luzzi

- Messing EM, Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. *Campbell's urology*. 7th ed. Philadelphia: WB Saunders, 1998:2327-410.
- Hamilton M. Cancer of the bladder presenting as "cystitis" or "prostatism". *Med J Aust* 1969; 2:89-91.
- Luzzi GA, Cranston D. Bladder carcinoma presenting as prostatitis syndrome. *Br J Urol Int* 2000;85:774-5.
- Solsona E, Iborra I, Ricos JV, et al. The prostate involvement as prognostic factor in patients with superficial bladder tumours. *J Urol* 1995;154:1710-13.

Accepted for publication 25 February 2000

### Atrial myxoma and HIV infection

EDITOR.—Atrial myxoma has not previously been reported in HIV infection. We describe a patient with advanced HIV disease who underwent surgery for this condition.

The patient was diagnosed with asymptomatic HIV infection in February 1987 when she was aged 50 years. Her CD4 count was  $690 \times 10^6/l$  at this time. HIV infection was acquired through sexual intercourse with a bisexual male partner. In December 1990 the CD4 lymphocyte count had fallen to  $190 \times 10^6/l$  and zidovudine monotherapy was started. This was continued until 1996 when she was prescribed a combination regimen. Co-trimoxazole was given for *Pneumocystis carinii* prophylaxis, but the patient deferred starting this until December 1992.

In February 1992 the patient was admitted to another hospital with an acute myocardial infarction which was successfully thrombolysed. Fasting lipids were within the normal range. There were no cardiac risk factors apart from smoking.

In September 1995 the patient experienced a syncopal episode. An echocardiogram revealed a mass in the left atrium consistent with a left atrial myxoma. A coronary angiogram showed normal coronary arteries. Surgical resection of the myxoma was recommended.

In December 1995 the patient's CD4 count was  $64 \times 10^6/l$ , but apart from oral candidiasis there had been no HIV related problems since diagnosis. Two leading UK HIV physicians were asked if they considered surgery to be advisable. They estimated the patient's likely survival from HIV disease to be 1-4 years. The risks of major heart surgery had to be balanced against the likelihood of recurrent symptoms from the myxoma in the next 1-4 years. The patient and her physician agreed to proceed with surgery.

On 4 December 1995 the patient underwent surgical resection of a pedunculated left atrial mass. Histological examination confirmed a benign atrial myxoma. The procedure was uncomplicated and she was discharged from hospital 4 days later. Annual cardiac review including an echocardiogram has shown no evidence of recurrence up to the present time. She remains free from cardiovascular symptoms. Her HIV disease is managed with combination therapy that consists of stavudine, lamivudine, and efavirenz. Current CD4 count is  $564 \times 10^6/l$  and viral load less than 50 copies/ml (Chiron bDNA v3.0).

Atrial myxoma is a rare tumour that is considered to be benign although recurrence and metastases have been described.<sup>1</sup> The myocardial infarction suffered by our patient may have been an embolic manifestation of the myxoma, and the normal serum lipids and normal coronary angiogram almost 4 years later would support this.

In 1995 expert opinion provided a very guarded prognosis for someone with a CD4 count of  $60 \times 10^6/l$  who had been exposed to a single antiretroviral agent, zidovudine. Today

there would be less debate over the merits of such a surgical procedure in this scenario, and this case demonstrates the excellent outcome that can be achieved with major surgery despite profound immunosuppression. The proved benefits of HAART (highly active antiretroviral therapy) have made it unacceptable to deny major surgical interventions to individuals with HIV.

ANDREW J SHAW  
KEN A MCLEAN

Department of Genitourinary Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF

Correspondence to: Dr Andrew Shaw, Department of Genitourinary Medicine, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ

- Desousa AL, Muller J, Campbell RL, et al. Atrial myxoma: a review of the neurological complications, metastases, and recurrences. *J Neurol Neurosurg Psychiatry* 1978;41:1119-24.

Accepted for publication 25 February 2000

### The association between receptive cunnilingus and bacterial vaginosis

EDITOR.—We are puzzled by the surprisingly little, if any, serious work done to explain the epidemiological enigma of high prevalence of bacterial vaginosis (BV) in lesbians,<sup>1</sup> and the oft observed, but as yet unconfirmed association between BV and receptive cunnilingus in women in general.

In a detailed study of 17 consecutive lesbians attending the department of genitourinary medicine at the Royal Sussex County Hospital in Brighton, bacterial vaginosis was found in six women (35%). Of nine lesbians who practised receptive cunnilingus in the previous 4 weeks, six (67%) had BV. By contrast, no BV was present in all eight women who did not practise oral sex (table 1).

In a parallel prospective study of 256 consecutive heterosexual female patients attending the same department, 55 (21%) were diagnosed as having BV. Of 111 women who practised receptive cunnilingus in the previous 4 weeks, 41 (37%) had BV. Of 145 women who did not have oral sex, only 14 (10%) had BV (table 1). In both groups there was strong association between BV and receptive cunnilingus ( $p < 0.001$ ).

The evidence associating bacterial vaginosis with oral sex is too strong to be ignored and repeatedly dismissed. The mouth is full of Gram positive and Gram negative organisms including *Bacteroides oralis* and, albeit in much smaller quantities, lactobacilli. These organisms are part of normal flora in the mouth, but are they normal to the vagina? Might the tiny amount of lactobacilli be enough to act as a phage which destroys the



Table 1 BV prevalence results

Lesbians	No of women	BV diagnosed
Total	17	6 (35%)
Practised receptive cunnilingus in previous 4 weeks	9	6 (67%)
Did not practise receptive cunnilingus	8	0
Heterosexual women	No of women	BV diagnosed
Total	256	55 (21%)
Practised receptive cunnilingus in previous 4 weeks	111	41 (37%)
Did not practise receptive cunnilingus in past 4 weeks	145	14 (10%)

endogenous healthy vaginal lactobacillus? In an interesting hypothesis, Blackwell described the possible effect of biochemical and microbial abnormalities in the vagina on BV recurrence.<sup>3</sup> She also quoted Berger's description of concordant vaginal floras in lesbian couples, suggestive of a mechanical transfer of an infectious agent.<sup>3</sup> Is it not possible for mouth organisms or hostile salivary enzymes to induce biological and microbial abnormalities in the vagina?

Furthermore, mechanical transfer of infectious agents in lesbian couples is most likely to occur via cunnilingus, a not uncommon practice among lesbians.

Cunnilingus is a common fact of sexual life. The dynamics of this practice vary considerably. If association between BV and oral sex is ever confirmed, would the degree of tongue penetration be a factor and should it be incorporated in the aetiology equation? Further and more extensive studies are certainly indicated.

S E TCHAMOUROFF  
S K PANJA

Department of Genitourinary Medicine, Royal Sussex  
County Hospital, Brighton BN2 5BE

Correspondence to: Dr Tchamouloff

- McCaffrey M, Varney PA, Evans B, *et al.* A study of bacterial vaginosis in lesbians. *Int J STD AIDS* 1997;8(Suppl 1):11.
- Blackwell AL. Vaginal bacterial phaginosity? Hypothesis. *Sex Transm Inf* 1999;75:352-3.
- Berger BJ, Kolton S, Zenilman JM, *et al.* Bacterial vaginosis in lesbians: a sexually transmitted disease. *Clin Infect Dis* 1995;21:1402-5.

Accepted for publication 25 February 2000

### Is partner notification in the public interest?

EDITOR,—This ethical debate<sup>1</sup> calls for comment.

Why did the clinicians only suspect AIDS? Surely at the second attendance the diagnosis was clinically obvious. As well as continuing treatment of candidiasis and starting prophylaxis of *Pneumocystis carinii* pneumonia, was not treatment for AIDS indicated? For fear of court proceedings a specimen of blood untested or surplus to routine haematological tests could have been stored to confirm, if necessary, the clinical diagnosis. A perspicacious defence lawyer could make much of this in terms of doctor thoroughness, cautiousness, and thoughtfulness—on behalf of his client.

In terms of contact tracing the word "disclosure" occurs repeatedly. Surely the first thing an index case is told when his/her cooperation is sought is that under no circumstances will their name be divulged. The contacts, when attending, will be refused any information regarding who has named them and immediately assured that the same confidentiality will be maintained if their cooperation is called for in the contact tracing process.

Only when it becomes widely known in a clinic that such confidentiality is thoroughly pursued will counterproductive fears be eliminated. With understanding and cooperation it can be done.

SAKINA RASHID

Department of Genito-Urinary Medicine, Sunderland  
Royal Hospital, Kayll Road, Sunderland SR4 7TP

- Winter AJ, Mullis D, Radcliffe KW, *et al.* Is partner notification public interest? *Sex Transm Inf* 1999;75:354-7.

### Sexual partner reduction and HIV infection

EDITOR,—We recently conducted a national urban random sample survey of 1400 men of sexually active age in the Dominican Republic to measure possible change in sexual behaviour. This sexual behaviour change (SBC) survey was prompted by results from the 1996 demographic and health survey, which found that 84.8% of a national random sample of Dominican men claimed that they had changed their behaviour in some way because of their fear of, or concern about, AIDS. The proportion of respondents reporting behaviour change such as becoming monogamous or reducing their number of sexual partners was about triple the proportion reporting condom adoption. In our SBC survey, 79% of respondents claimed to have changed behaviour because of concern about AIDS. A majority (52.2%) said they had become monogamous or reduced their number of sexual partners. This was followed by condom adoption (14.6%), only having sexual relations with a person they know (13.9%); avoiding relations with "prostitutes" (9.0%); or becoming abstinent (1.6%). A small proportion (2.8%) had not yet begun to have sexual relations. As with the Dominican DHS findings, we see that most answers are classifiable as behaviour change, as distinct from condom adoption. This follows a pattern found in recent studies in countries such as Uganda and Zambia. A recent review of findings from behavioural change surveys in 16 countries in Africa, Latin America, and the Caribbean shows that partner reduction is more often reported than condom adoption.<sup>1</sup> If sizeable numbers of men reduce their number of sexual partners, can this have significant impact on HIV infection rates? Urban HIV seroprevalence among the general or low risk Dominican population seems to have stabilised at the 1.9-2.0% level since 1995, according to the US Census Bureau. Recent studies that have modelled the impact of different interventions on HIV infection rates in east Africa suggest that reduction in number of partners can have a great impact on averting HIV infections, in fact greater than either condom use or treatment of STDs.<sup>2,3</sup> Of course, impact of partner reduction on HIV infection rates would be espe-

cially strong where there is relatively high HIV seroprevalence among potential partners. In view of these modelling studies as well as population based surveys such as the two cited from the Dominican Republic, perhaps there ought to be greater equity in resource allocation between HIV/AIDS prevention programmes promoting behaviour change—such as monogamy/fidelity or at least reduction of number and frequency of change of sex partners—and far more familiar programmes that promote and provide condoms.

EDWARD C GREEN  
ALDO CONDE

2807 38th Street, NW Washington, DC 20007, USA

Correspondence to: Dr Green

- Gardner R, Blackburn RD, Upadhyay UD. *Closing the condom gap. Population Reports, Series H.* Baltimore: Johns Hopkins University, April 1999.
- Bernstein RS, Sokal DC, Seitz ST, *et al.* Simulating the control of a heterosexual HIV epidemic in a severely affected east African city. *Interfaces* 1998;28:101-26.
- Robinson NJ, Mulder DW, Auvert B, *et al.* Modelling the impact of alternative HIV intervention strategies in rural Uganda. *AIDS* 1995;9:1263-70.

Accepted for publication 25 February 2000

### Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study

EDITOR,—To assess the features of AIDS defining illnesses during the HAART era versus those observed before the introduction of HAART, the characteristics of 72 consecutive patients, diagnosed in 1997-9, were compared with those of 144 subjects randomly selected from the 436 patients diagnosed from 1985 to 1995, in a case-control study.

An impressive drop in AIDS diagnosis was seen shortly after the introduction of HAART, with only 38, 21, and 13 cases per ~1000 patient years observed in 1997, 1998, and 1999 respectively, versus a mean frequency >60 cases per ~1000 patient years, demonstrated during 1991-5. A tendency towards an increased incidence of female sex was shown in 1997-9 compared with 1985-95 (33.3% versus 27.1%), together with a rise of mean CD4+ lymphocyte count (86.8 (SD 99.4) versus 72.1 (93.7) cells ×10<sup>6</sup>/l), while an increase in the mean patient age was highly significant (39.8 (8.3) versus 34.6 (7.7) years; p<0.0001). When considering the exposure to HIV infection, drug abuse became significantly less important in the HAART era (p<0.05), while heterosexual transmission was notably increased (34.7% versus 13.2% of cases; p<0.0003). The distribution of AIDS defining disorders during the HAART era showed a tendency to a reduction in cytomegalovirus, cryptococcosis, mycobacteriosis, cryptosporidiosis, and HIV encephalopathy, while a relative increase in pneumocystosis, oesophageal candidiasis, wasting syndrome, tuberculosis, and non-Hodgkin's lymphoma was found; neurotoxoplasmosis and Kaposi's sarcoma were stable (table 1). However, while pneumocystosis, *Candida* oesophagitis, neurotoxoplasmosis, and Kaposi's sarcoma represented the four most frequent AIDS related events in both study periods, cytomegalovirus, HIV encephalopathy, cryptococcosis, and mycobacteriosis (which ranked fifth to eighth in

Table 1 AIDS defining events and mean CD4+ lymphocyte count at disease occurrence, in the two considered time periods

AIDS defining diseases	Years 1985–95 (144 patients, 151 diseases)		Years 1997–9 (72 patients, 76 diseases)	
	No of diseases (%)	Mean CD4+ count (cells ×10 <sup>6</sup> /l (SD))	No of diseases (%)	Mean CD4+ count (cells ×10 <sup>6</sup> /l (SD))
<i>Pneumocystis carinii</i> pneumonia	40 (26.5)	58.6 (49.0)	22 (28.9)	62.4 (72.1)
Oesophageal candidiasis	21 (13.9)	71.3 (62.6)	16 (21.0)	129.9 (98.1)
Neurotoxoplasmosis	17 (11.3)	79.9 (62.1)	9 (11.8)	75.6 (39.2)
Kaposi's sarcoma	15 (9.9)	98.1 (101.3)	7 (9.2)	133.3 (68.3)
Cytomegalovirus (retinitis or disseminated disease)	10 (6.6)	77.3 (100.2)	1 (1.3)	48
HIV encephalopathy (AIDS-dementia complex)	7 (4.6)	81.1 (45.9)	2 (2.6)	102.0 (29.7)
Extrapulmonary cryptococcosis	6 (4.0)	25.2 (19.4)	0 (—)	—
Disseminated mycobacteriosis	5 (3.3)	62.4 (50.5)	1 (1.3)	78
Wasting syndrome	5 (3.3)	38.4 (41.1)	5 (6.6)	121.2 (54.0)
Non-Hodgkin's lymphoma or primary CNS lymphoma	5 (3.3)	116.3 (41.1)	4 (5.3)	125.9 (71.2)
Cryptosporidiosis	4 (2.7)	38.3 (10.2)	0 (—)	—
Tuberculosis (pulmonary or disseminated disease)	3 (2.0)	148.2 (51.4)	5 (6.6)	289.3 (71.2)
Other AIDS defining events	13 (8.6)	55.3 (48.9)	4 (5.3)	73.3 (101.1)

frequency during the pre-HAART era), virtually disappeared after the introduction of HAART (28 versus four overall cases;  $p < 0.007$ ), together with cryptosporidiosis. Neoplasms and HIV related disorders (encephalopathy and wasting syndrome), showed a slightly increased frequency during the HAART era (16.8% and 9.2% during 1997–9, versus 13.2% and 7.9% respectively, during the pre-HAART period). A considerable trend to increased mean CD4+ count was found during the HAART era for all AIDS related illnesses considered, except neurotoxoplasmosis. However, this increase in CD4+ count was significant only for *Candida oesophagitis* ( $p < 0.04$ ), wasting syndrome ( $p < 0.03$ ), and tuberculosis ( $p < 0.03$ ), probably because of small patient samples. Only seven of the 72 patients who developed AIDS since 1997 (9.7%), were effectively treated with HAART for more than 3 months before diagnosis; in the remaining 65 cases HIV infection was detected concurrently with an AIDS defining event in subjects who were unaware of their condition (40 cases), or refused HAART or carried out it with poor adherence (25 patients).

Although a sharp decline in the incidence of multiple AIDS defining events was demonstrated since the introduction of HAART, the distribution of primary AIDS associated diseases showed limited modifications.<sup>1–3</sup> An increased incidence of women, a higher patient age, a greater role for heterosexual transmission compared with injecting drug addiction, and a rise in CD4+ count were disclosed by us in the HAART era compared with the pre-HAART period. Appreciable modifications of the spectrum of AIDS associated illnesses were also observed during the HAART era (a drop of cytomegalovirus, cryptococcosis, mycobacteriosis, cryptosporidiosis, and HIV encephalopathy, with a parallel increase in pneumocystosis, oesophageal candidiasis, wasting syndrome, tuberculosis, and non-Hodgkin's lymphoma), together with a considerable trend towards an increased mean CD4+ count at diagnosis, as previously noted.<sup>2,5</sup> Disorders which are directly or indirectly associated with HIV damage itself, AIDS related neoplasms, and opportunistic diseases occurring with a less profound immunodeficiency, show a substantially stable or even increasing incidence among newly diagnosed cases of AIDS.<sup>1,2,4</sup> However, opportunistic diseases related to a severe immunodeficiency are still frequent among AIDS defining events, since the majority of cases identified during the

HAART era occur in patients who are not aware of their disease, or fail HAART. Only early detection and aggressive treatment of HIV infection may definitively improve the epidemiology of AIDS; a continued surveillance of AIDS related disorders remains critical for the implementation of therapeutic and prophylactic strategies.

ROBERTO MANFREDI  
FRANCESCO CHIODO

Department of Clinical and Experimental Medicine,  
Division of Infectious Diseases, University of Bologna,  
Bologna, Italy

Correspondence to: Dr Roberto Manfredi, Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna, S Orsola Hospital, Via Massarenti, 11, I-40138 Bologna, Italy

- 1 Palella FJ, Delaney KM, Moorman AC, *et al.* Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853–60.
- 2 Forrest DM, Seminari E, Hogg RS, *et al.* The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. *Clin Infect Dis* 1998;27:1379–85.
- 3 Mocroft A, Sabin CA, Youle M, *et al.* Changes in AIDS-defining illness in a London Clinic, 1987–1998. *J Acquir Immune Defic Syndr Hum Retroviral* 1999;21:401–7.
- 4 Franceschi S, Dal Maso L, la Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. *Int J Cancer* 1999;83:481–5.
- 5 Law MG, De Winter L, McDonald A, Cooper DA, Kaldor JM. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. *AIDS* 1999;13:263–9.

Accepted for publication 25 February 2000

## BOOK REVIEWS

**Hustling for Health. Developing Services for Sex Workers in Europe.** Pp 83; Price 10 euros. The European Network for HIV/STD Prevention in Prostitution (EUROPAP/TAMPEP), 1998. Contact Judith Kilvington/Helen Ward, Coordinating Centre, European Network for HIV/STD Prevention in Prostitution, Department of Epidemiology and Public Health, Imperial College School of Medicine, London W2 1PG (tel: 0207 594 3315; fax: 0207 402

2150; email: europap@ic.ac.uk). (Also available in nine other European languages (Danish, Finnish, Flemish, French, German, Greek, Italian, Portuguese, Spanish), and the full text (without illustrations) can be found online on the website (<http://www.med.ic.ac.uk/df/dfhm/europap/hustling/press.htm>).

How do you begin to address the sexual health needs of commercial sex workers (CSWs)? Here you will find (most of) the answers. This immensely practical book is essential for those setting up an outreach service, or simply wishing to know more about commercial sex work. It is the outcome of a series of projects and workshops, written by workers providing services to CSWs throughout Europe, and draws from the lessons learnt by these pioneering workers and clients. It is written with great clarity and frankness. The A4 layout is bold, imaginative, and attractive, with illustrations of promotional literature. Its European inclusiveness means that sadly it cannot be specific regarding, for example, the law as it applies to commercial sex. It does, however, give the broad framework with which providers must acquaint themselves wherever they work. It takes us through the steps; sources of funding, the scope of the service, useful contacts, where to make contact with CSWs, and so on. Importantly, in the current climate there are sections on evaluation and monitoring of the service, the legal and political context of the work, and dealing with the media. It stresses the heterogeneous nature of commercial sex workers whether male, female, or transsex, and the spectrum of commercial sex venues. Peer educator programmes are covered in some detail.

There are fascinating pieces of practical advice—for example, cooperate with police, but don't be identified too closely with law enforcement. Advising police of your outreach vehicle's registration number may prevent you being stopped for kerb crawling!

You can set up a flawless screening service and find only a few CSWs attend. The book reminds us middle class, health aware professionals that, for many, sexual health is not a priority. We are perplexed when faced with "indifference, hostility and self destructive behaviour"; that her next fix, a roof over her head, or the desire to have a baby might be more important to the CSW than the nebulous risk of HIV. Address some of these needs and you have the carrot to attract attention to and confidence in your service. The spin off is that clients can then benefit from STD screening and safer sex advice. Simply providing toilets and somewhere safe to have a cup of tea may be enough for some.

I would have liked to see a further reading list, but this book fulfils its remit excellently.

MARY STEVENSON

The Guest Hospital, Tipton Road, Dudley DY1 4SE

**Children in Mind.** Pp 106; £20. London: Audit Commission, 1999. ISBN 186240-8.

The Audit Commission, established in 1983, reports on a 2 year study of the specialist Child and Adolescent Mental Health Services (CAMHS) as provided by local authorities and NHS trusts. Local information has been processed centrally to generate facts and figures and comparative data.



The 13 000 bodies providing CAMHS spend £100 billion (sic) of public money annually in England and Wales. The Commission's team of seven have met with external advisers with a view to shaping of the audit, its comments, and guidance. The aim is to achieve economy with efficiency and effectiveness. The report is in five chapters and five helpful appendices. It lists 71 references and has an index.

Under the heading "The changing context" it is revealed that one in five children and adolescents (alas, not defined for females and males) suffer from a wide range of mental health problems of variable degrees of severity from social ineptitude through psychological to severe psychiatric disorder. Strong links are noted with juvenile crime, alcohol and drug abuse, eating disorders, and of course self harm.

The key components of the CAMHS are viewed as four "tiers": (a) Those providing primary intervention, eg, GPs, health visitors, residential social workers, juvenile justice workers, school nurses, and teachers. (b) Professional providers of services, eg, clinical and educational psychologists, paediatricians, child psychiatric nurses in the community, and child psychiatrists. (c) High grade specialist services for severe, complex and persistent disorders, eg, child psychiatrists, community psychiatric nurses, psychotherapists, occupational therapists and art, music, and drama therapists. (d) Consists of hospital services especially unnamed "highly specialised outpatient teams". This clearly applies to accident and emergency departments, obstetric and gynaecology departments, and genitourinary medicine departments. These deal very adequately with self poisoning episodes, premarital abortions, and sexually acquired infection, but fail to see the underlying behaviour as but one manifestation of an ongoing complex of medicosocial pathology. Clearly, services for the care of our adolescents, unlike paediatrics and geriatrics, are seriously fractionated.

What follows should help the holistically minded hospital doctor to increase his awareness and skills and so make more regular and early use of referral routes and emergency cover arrangements provided by developing CAMHS.

It is clear that in many areas there is an urgent need to plan how best to meet unmet needs, including appropriate monitoring. The final chapter of this book purports to show how, with national support, highly active local coordination can establish and advance improvements. Recommendations are provided. There are opportunities for masterly leadership.

As the first specialty to be nationalised in the United Kingdom, genitourinary medicine has come a long way from the days of "pox doctoring" in "clap clinics". Has the time come for it to give a lead in the development of more appropriate and comprehensive services for adolescents?

For the long sighted and adventurous GU physician this book suggests how to begin.

R S MORTON

**Laboratory Diagnosis of Sexually Transmitted Diseases.** Pp 135 (available in English, French, and Spanish); Sw fr 35/\$31.50, in developing countries Sw fr 24.50. Geneva: World Health Organisation, 1999. ISBN 92 4 154501 1.

"Venereal diseases are like the fine arts—it is pointless to ask who invented them." (Voltaire, *Dictionnaire philosophique*).

Sexually transmitted diseases (STDs) now rank among the top ten diseases for which adults in developing countries seek health care. The economic burden of STDs on both developed and developing countries is enormous. Infection with conventional STDs is a risk factor for transmission of infection with HIV, and therefore for the development and spread of the AIDS

It is imperative that laboratory services are available to guide the clinician to the correct diagnosis and treatment of these conditions, and to give an accurate epidemiological picture of their prevalence in a particular community in order to target relevant populations and ensure optimal and economic use of available resources. Yet, the availability of both funds and technology varies widely between different settings.

This manual sets out to give comprehensive guidance on tests available and applicable to the level of expertise and funding available.

Nine chapters cover the major STDs, encompassing bacterial and viral infections, and under the umbrella of vaginitis in adults; trichomoniasis, candidiasis, and bacterial vaginosis. Each chapter begins with a brief description of the microbiology of the infective agent and the clinical spectrum of disease. The detail given is not consistent, being comprehensive for chancroid and granuloma inguinale, and surprisingly brief for HIV and chlamydia by way of contrast. Then follows a description of collection and transport requirements, and of techniques for diagnosis. The emphasis is on tests that are possible in a reasonably well equipped laboratory, but not one capable of reference facilities. Tests that are suitable for use in the field are highlighted. An evaluation of sensitivity and specificity is also given. Other tests available in central or reference laboratories are mentioned in brief, usually with supporting references.

Two annexes cover media, reagents and stains, and details of equipment required to diagnose each condition. A third annex is an interesting table of which tests should be available at "peripheral," "intermediate," and "central" laboratories.

Overall, this manual is to be welcomed as an educational and reference source for medical microbiologists, technologists, and clinicians. However, I would recommend that the authors "road test" the manual to discover omissions in technical detail that would prevent the sole use of the manual in the field.

Indifferent colour reproduction detracts from the quality of the text—for example, blue reactions appearing as red in the figure.

For the next edition, a chapter on basic microscopical techniques and another on the general principles and interpretation of laboratory tests would provide useful introductions to an otherwise excellent publication.

GEOFFREY L RIDGWAY

Department of Clinical Microbiology, UCH Accident and Emergency Building, London WC1E 6DB

## CD-ROM REVIEWS

**Topics in International Health. HIV/AIDS.** London: The Wellcome Trust, CAB International, 1998. Institutional licence £120; individual licence £30

This is a superb CD Rom covering various aspects of HIV and AIDS by means of interactive tutorials. It is clear, concise, and up to date and has tutorials under the following headings: Overview, Biology of HIV, Natural history, Infections and malignancies, Epidemiology, Transmission and risk factors, Prevention, Diagnosis and monitoring, Women and children, Management, Social and psychological issues.

Each tutorial is self contained (which does lead to some duplication) and has self assessment questions—usually with click and drag matching of statements or true/false boxes. The information itself is well illustrated and contains animations and a video clip, together with further information/annotations in pop up boxes. At the end of each section there is a set of summary points, a reading list, and further activities such as internet sites.

There is a searchable picture index which allows you to search, view, and save sets of images for reference and lectures (although copyright does apply), and a glossary of terms.

Overall this is an excellent CD Rom providing good information, presented in an attractive and usable way, with a wealth of illustrations. I would strongly recommend it.

SARAH EDWARDS

Department of GU Medicine, West Suffolk Hospital, Bury St Edmunds, Suffolk, IP33 2QZ

**Facing HIV: A Resource for Primary Healthcare.** Contributors: Annalisa Rossi, Margaret Allen, Sirkka-Liisa Nurkkala, Begona Gros, Cristina Martinez-Bueno. £29.38. East Lancashire Health Authority, South Lancashire Health Authority, University of Central Lancashire, The Faculty of Health, and The Centre for Learning Technologies at the University of Central Lancashire

This is an interesting CD Rom which, gives a very personal guide to issues surrounding HIV—covering the experience of the patient, carer and healthcare professionals.

Four main sections cover the following areas: Living with HIV, Is HIV different? Loss, grieving and bereavement, Supporting people affected by HIV.

These areas are illustrated by short video clips and backed up by further information. Basic information is given about HIV treatment, the impact of diagnosis and of ill health, and other related topics. Unfortunately the information about drug treatment is already outdated and there is no search facility.

The strength of this CD Rom is the view it gives of the emotional responses to HIV and the strategies for coping with the infection from the viewpoint of those involved. The academic content is limited but it is worth a look for the patient perspectives.

SARAH EDWARDS

Department of GU Medicine, West Suffolk Hospital, Bury St Edmunds, Suffolk, IP33 2QZ

---

## NOTICES

---

### 9th International Congress on Infectious Diseases, 9–12 April 2000, Buenos Aires, Argentina

Further details: International Society for Infectious Diseases, 181 Longwood Avenue, Boston, MA 02115, USA (tel: (617) 277-0551; fax: (617) 731-1541; email: isidbos@aol.com).

### Sexually Transmitted Diseases in a Changing Europe, 14–15 April 2000, Rotterdam, The Netherlands

Further details: Mediscon, Organisation for Medical Congresses, PO Box 113, 5660 AC Geldrop, Netherlands (tel: +31-(0)40-2852212; fax: +31-(0)40-2851966; email: MEDISCON@IAEhv.nl).

### 20th Scientific Conference of Venereological Section of the Polish Society of Dermatologists, Bialystok, 28–30 April 2000

The conference will be on epidemiological and clinical aspects of sexually transmitted infections. Further details: Dept Dermatology and Venereology, Sw Rocha 3, 15-879 Bialystok, Poland (tel/fax: (085) 7422778; email: bozchod@amb.ac.bialystok.pl).

### Joint meeting of the MSSVD and the ASTDA, 3–7 May 2000, Baltimore Marriott Inner Harbor Hotel, Baltimore, Maryland, USA

Further details: Dr Keith Radcliffe, honorary assistant secretary, MSSVD (fax: +44(0) 121-237 5729; email: k.w.radcliffe@bham.ac.uk).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Advanced Course in Fetal Medicine, 22–24 May 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Advanced Course for Obstetricians and Gynaecologists, 19–23 June 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### Australasian Sexual Health Conference, Ven Troppo, Carlton Hotel, Darwin, Northern Territory, 21–24 June 2000

Further details: Shirley Corley, Conference manager, Dart Associates, PO Box 781, Lane Cove, 2066 NSW, Australia (tel: 02 9418 9396/97; fax: 02 09418 9398; email: dartconv@mpx.com.au).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Caring for Sexuality in Health and Illness (for healthcare professionals and nurses), jointly with Association of Psychosexual Nursing 27 June 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### Sexual Health and HIV Conference: Facing the Millennium, Portsmouth Marriott Hotel, Portsmouth, 28 June 2000

Further details: Rebecca Mitchell (tel: 023 9286 6796; fax: 023 9286 6769).

### 6th ESC Congress on Contraception in the Third Millennium: a (R)Evolution in Reproductive and Sexual Health, Ljubljana, Slovenia, 28 June–1 July 2000

Further details: Orga-Med Congress Office, Mr Peter Erard, Essenestraat 77, B-1740 Ternat, Belgium (tel: +32 2 582 08 52; fax: +32 2 582 55 15; email: orgamed@village.uunet.be).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, New Horizons in Recurrent Pregnancy Loss, 29 June–1 July 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Bereavement, 5 July 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### Imperial College School of Medicine, Division of Paediatrics, Obstetrics, and Gynaecology, Advances in Obstetric Medicine: International Meeting of Obstetric Medicine Societies (satellite to ISSHP), Paris, 6–7 July 2000

Further details: Symposium Office, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG (tel: 020 8383 3904; fax: 020 8383 8555; email: sympreg@ic.ac.uk).

### XIII International AIDS Conference, 9–14 July 2000, Durban, South Africa

Further details: Congrex Sweden AB, PO Box 5619, Linnegatan 89A, 114 86 Stockholm, Sweden (tel: +46 8 459 6600; fax: +46 8 661 91 25; email: aids2000@congrex.se).

### The Management of Genito-urinary Infections in Women, Royal Society of Medicine, London, 13–14 July 2000

### 3rd Congress of the Baltic Association of Dermatovenereology, 7–9 September 2000, Riga, Latvia

Further details: Professor Andris Y Rubins, Department of Dermatovenereology, Medical Academy of Latvia, K Valdemara Street, 76–75, Riga, LV-1013, Latvia (tel: +(371) 7370395; fax: +(371) 7361615; email: arubins@apollo.lv).

### National NCCG Uptake Meeting, Bromsgrove Stakis Hotel, 23–24 September 2000

Further details: Kathy Taylor (tel: 01384 235207; email: palmtraining@tesco.net).

### Consortium of Thai Training Institutes for STDs and AIDS—10th STDs/AIDS diploma course, Bangkok Hospital, Bangkok (30 Oct–12 Nov) and Prince of Songkla University, Hat Yai, Thailand (13–23 Nov) 30 October–23 November 2000

Further details: Hat Yai Secretariat, Dr Verapol Chandeying, Dept of OB-GYN, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand (fax: (66-74) 446 361; email: cverapol@ratree.

psu.ac.th or Bangkok Secretariat, Dr Thanit Palanuvej, Bangkok Hospital, 189 Sathorn Road, Bangkok 10120, Thailand (fax: (66-2) 286 3013; email: pthanit@email.ksc.net).

### Consortium of Thai Training Institutes for STDs and AIDS—International Reunion and Refresher Course on Sexual Health, Lee Garden Plaza Hotel, Hat Yai, Thailand 24–26 November 2000

Further details: Hat Yai Secretariat, Dr Verapol Chandeying, Dept of OB-GYN, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand (fax: (66-74) 446 361; email: cverapol@ratree.

psu.ac.th or Bangkok Secretariat, Dr Thanit Palanuvej, Bangkok Hospital, 189 Sathorn Road, Bangkok 10120, Thailand (fax: (66-2) 286 3013; email: pthanit@email.ksc.net).

---

## CORRECTION

---

An error occurred in an original article by Hughes *et al* that appeared in the February issue of the journal (2000;76:18–24). In the participants section under West Midlands, "Dr Wade, Coventry and Warwickshire Hospital" should read "Dr Wade and Dr Allan, Coventry and Warwickshire Hospital."

---

## CURRENT PUBLICATIONS

---

Selected titles from recent reports published worldwide are arranged in the following sections:

*Gonorrhoea*  
*Chlamydia*  
*Candidiasis*  
*Bacterial vaginosis*  
*Trichomoniasis*  
*Pelvic inflammatory disease*  
*Syphilis and other treponematoses*  
*Hepatitis*  
*Herpes*  
*Human papillomavirus infection*  
*Cervical cytology and colposcopy*  
*Other sexually transmitted infections*  
*Public health and social aspects*  
*Microbiology and immunology*  
*Dermatology*  
*Miscellaneous*

---

## Gonorrhoea

---

***Neisseria gonorrhoeae* infections in girls younger than 12 years of age evaluated for vaginitis.**

RA SHAPIRO, CJ SCHYBERT, RM SIEGEL. *Pediatrics* 1999;104:E721-30

**Opa expression correlates with elevated transformation rates in *Neisseria gonorrhoeae*.**

SA HILL. *J Bacteriol* 2000;182:171-8

---

## Chlamydia

---

***Chlamydia trachomatis* infection as a risk factor for invasive cervical cancer.**

P KOSKELA, T ANTTILA, T BJORGE *et al.* *Int J Cancer* 2000;85:35-9

**Screening for *Chlamydia trachomatis* in subfertile women.**

S MACMILLAN, A TEMPLETON. *Hum Reprod* 1999;14:3009-12

**Analysis of *Chlamydia trachomatis* serovars in endocervical specimens derived from pregnant Japanese women.**

J IKEHATA, K NUMAZAKI, S CHIBA. *Fems Immunol Med Microbiol* 2000;27:35-42

**Molecular epidemiology of genital *Chlamydia trachomatis* infection in high-risk women in Senegal, West Africa.**

K STURMRANIREZ, H BRUMBLAY, K DIOP *et al.* *J Clin Microbiol* 2000;38:138-45

**Evaluation of a rapid assay for detection of *Chlamydia trachomatis* infections in outpatient clinics in South Kalimantan, Indonesia.**

S WIDJAJA, S COHEN, WE BRADY *et al.* *J Clin Microbiol* 1999;37:4183-8

**Seroactivity to *Chlamydia trachomatis* Hsp10 correlates with severity of human genital tract disease.**

D LAVERDA, LN ALBANESE, PE RUTHER *et al.* *Infect Immun* 2000;68:303-9

**Immunogenic and protective ability of the two developmental forms of *Chlamydiae* in a mouse model of infertility.**

S PAL, J RANGEL, EM PETERSON, LM DELAMAZA. *Vaccine* 1999;18:752-63

**Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains.**

H SU, R MESSER, W WHITMIRE. *Infect Immun* 2000;68:192-6

**Isolates of *Chlamydia trachomatis* that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane.**

RJ SUCHLAND, DD ROCKEY, JP BANNANTINE, WE STAMM. *Infect Immun* 2000;68:360-7

**The intercellular adhesion molecule type-1 is required for rapid activation of T helper type 1 lymphocytes that control early acute phase of genital chlamydial infection in mice.**

JU IGIETSEME, GA ANANBA, J BOLIER *et al.* *Immunology* 1999;98:510-8

---

## Candidiasis

---

**Species and genotypic diversities and similarities of pathogenic yeasts colonizing women.**

JP XU, CM BOYD, E LIVINGSTON *et al.* *J Clin Microbiol* 1999;51:3835-50

**Isolated candidal prostatitis.**

A ELERT, R VONKNOBLOCH, R NUSSER *et al.* *J Urol* 2000;163:244

**Multilocus genotypes and DNA fingerprints do not predict variation in azole resistance among clinical isolates of *Candida albicans*.**

LE COWEN, C FIRJUSINGH, RC SUMMERBELL *et al.* *Antimicrob Agents Chemother* 1999;43:2930-42

---

## Bacterial vaginosis

---

**Prevalence of bacterial vaginosis and correlation of clinical to gram stain diagnostic criteria in low risk pregnant women.**

E GRATACOS, F FIGUERAS, M BARRANCO *et al.* *Eur J Epidemiol* 1999;15:913-6

**Direct or referral microscopy of vaginal wet smear for bacterial vaginosis: experience from an STD clinic.**

CS PETERSEN, AG DANIELSEN, J RENNEBERG. *Acta DermatoVenerol* 1999;79:473-4

---

## Trichomoniasis

---

**Improved diagnosis of *Trichomonas vaginalis* infection by PCR using vaginal swabs and urine specimens compared to diagnosis by wet mount microscopy, culture and fluorescent staining.**

C VANDERSCHIE, A VANBELKUM, L ZWIJGERS *et al.* *J Clin Microbiol* 1999;37:4127-34

**Use of spun urine to enhance detection of *Trichomonas vaginalis* in adolescent women.**

DR CLAKE, A DUGGAN, A JOFFE. *Arch Pediat Adolesc Med* 1999;153:1222-5

**Identification of *Trichomonas vaginalis*  $\alpha$ -actinin as the most common immunogen recognized by sera of women exposed to the parasite.**

MF ADDIS, P RAPPELLI, AMP DEANDRADE *et al.* *J Infect Dis* 1999;180:1727-30

---

## Pelvic inflammatory disease

---

**Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database.**

KT ZONDERVAN PL YUDKIN, MP VESSEY *et al.* *Br J Obstet Gynaecol* 1999;106:1149-55

**Patterns of diagnosis and referral in women consulting for chronic pelvic pain in UK primary care.**

KT ZONDERVAN, PL YUDKIN, MP VESSEY *et al.* *Br J Obstet Gynaecol* 1999;106:1156-61

---

## Syphilis and other treponematoses

---

**Response to standard syphilis treatment in patients infected with the human immunodeficiency virus.**

J BORDON, C MARTINEZVAZQUEZ, J DELAFUENTEAGUADO *et al.* *Eur J Clin Microbiol Infect Dis* 1999;18:729-32

**Identification of *Treponema pallidum* subspecies *pallidum* in a 200-year-old skeleton specimen.**

CJ KOLMAN, A CENTRURIONLARA, SA LUKEHART *et al.* *J Infect Dis* 1999;180:2060-3

**Validation of the INNO-LIA syphilis kit as a confirmatory assay for *Treponema pallidum* antibodies.**

A EBEL, L VANNESTE, M CARDINAELS *et al.* *J Clin Microbiol* 2000;38:215-9

---

## Hepatitis

---

**Low risk of vertical transmission of hepatitis C virus by breast milk.**

S POLYWKA, M SCHROTER, HH FEUCHT *et al.* *Clin Infect Dis* 1999;29:1327-9

**Urine from chronic hepatitis B virus carriers: implications for infectivity.**

M KNUTSSON, K KIDDLJUNGGREN. *J Med Virol* 2000;60:17-20

---

## Herpes

---

**Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers.**

W MCFARLAN, L GWANZURA, MT BASSETT *et al.* *J Infect Dis* 1999;180:1459-65

**Relation between herpes simplex viruses and human immunodeficiency virus infections.**

JL SEVERSON, SK TYRING. *Arch Dermatol* 1999;135:1393-7



**Persistent stress as a predictor of genital herpes recurrence.**

F COHEN, ME KEMENY, KA KEARNEY *et al.* *Arch Intern Med* 1999;159:2430–6

**Rapid detection of HSV from cytologic specimens collected into ThinPrep fixative.**

MD FIELGAN, CF VILLAMIL, SR MANDAVILLI *et al.* *Acta Cytol* 1999;43:1034–8

**Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod.**

RL MILLER, LM IMBERTSON, MJ REITER, JF GERSTER. *Antivir Res* 1999;44:31–42

**Protective immune correlates can segregate by vaccine type in a murine herpes model system.**

JI SIN, V AYYAVOO, J BOYER *et al.* *Int Immunol* 1999;11:1763–74

**Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection.**

T GYOTOKU, L AURELIAN, AR NEURATH. *Antiviral Chem Chemother* 1999;10:327–32

**Co-infection of acyclovir-resistant and acyclovir-sensitive herpes simplex type 2 virus strains in BS-C-1 cells.**

K KEYWAN, E KATZ. *Intervirology* 1999;42:247–51

**Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.**

EL PARR, MB PARR. *Immunology* 1999;98:639–45

**Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C.**

JC MESTER, TA TWOMEY, ET TEPE, DI BERNSTEIN. *Vaccine* 1999;18:875–83

**Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy.**

AM THACKRAY, HJ FIELD. *Antimicrob Agents Chemother* 2000;44:97–110

**Repression of viral transcription during herpes simplex virus latency.**

CM PRESTON. *J Gen Virol* 2000;81:1–20

**The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain.**

JC WHITBECK, MI MUGGERIDGE, AH RUX *et al.* *J Virol* 1999;73:9879–90

**Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frame shift mutations.**

JA LILJEQVIST, B SVENNERHOLM, T BERGSTROM. *J Virol* 1999;73:9796–809

**Potential role for luman, the cellular homologue of herpes simplex virus VPA16 ( $\alpha$  gene trans-inducing factor) in herpesvirus latency.**

R LU, V MISRA. *J Virol* 2000;74:934–43

**Granzyme A, a noncytotoxic component of CD8(+) cell granules, restricts the spread of herpes simplex virus in the peripheral nervous systems of experimentally infected mice.**

RA PEREIRA, MM SIMON, A SIMMONS. *J Virol* 2000;74:1029–42

**Intracellular localization of the UL31 protein of herpes simplex virus type 2.**

HY ZHU, H YA, ADA, YM JIANG *et al.* *Arch Virol* 1999;144:1923–36

**Human papillomavirus infection**

**Pernicious papillomavirus infection.**

RD BURK. *N Engl J Med* 1999;341:1687

**Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.**

KL WALLIN, F WIKLUND, T ANGSTROM *et al.* *N Engl J Med* 1999;341:1633–8

**Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.**

EL FRANCO, LL VILLA, JP SOBRINHO *et al.* *J Infect Dis* 1999;180:1415–23

**HPV transmission—still feeling the way.**

A MINDEL, R TIDEMAN. *Lancet* 1999;354:2097

**HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.**

TC WRIGHT, L DENNY, L KUHN *et al.* *JAMA* 2000;283:81–6

**HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.**

M SCHIFFMAN, R HERRERO, A HILDESHEIM *et al.* *JAMA* 2000;283:87–93

**Human papillomavirus testing for primary cervical cancer screening.**

J CUZICK. *JAMA* 2000;283:108–13

**HPV-based cervical cancer screening in a population at high risk for HIV infection.**

SD WOMACK, ZM CHIRENJE, L GAFFIKIN *et al.* *Int J Cancer* 2000;85:206–10

**Screening for cervical neoplasia by self-assessment for human papillomavirus DNA.**

P HILLEMANN, R KIMMIG, U HUTTEMANN *et al.* *Lancet* 1999;354:1970

**Spontaneous evolution of human papillomavirus infection in the uterine cervix—a prospective observational study.**

E PARASKEVAIDIS, SM KALANTARIDOU, I GEORGIU *et al.* *Anticancer Res* 1999;19:3473–8

**Seroreactivity to human papillomavirus type 16, 18, 31 and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions.**

L WIDEROFF, M SCHIFFMAN, P HADERER *et al.* *J Infect Dis* 1999;180:1424–8

**Anal intraepithelial neoplasia.**

JH SCHOLEFIELD. *Br J Surg* 1999;86:1363–4

**A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients.**

RJC GILSON, JL SHUPACK, AE FRIEDMANKIEN *et al.* *AIDS* 1999;13:2397–2404

**Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters.**

CS BRADY, MF DUGGANKEEN, JA DAVIDSON *et al.* *J Gen Virol* 1999;80:3233–40

**Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types.**

HC LAI, CA SUN, MH YU *et al.* *Int J Cancer* 1999;84:553–7

**Seroepidemiology of human papillomavirus type 73: a sexually transmitted low-risk virus.**

KL WALLIN, GJ VANDOORNUM, A ANDERSSONELLSTROM *et al.* *Int J Cancer* 2000;85:353–7

**Improved amplification of genital human papillomaviruses.**

OE GRAVITT, CL PEYTON, TQ ALESSI *et al.* *J Clin Microbiol* 2000;38:357–61

**Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopic atypia.**

J KONYA, G VERESS, A JUHASZ *et al.* *J Clin Microbiol* 2000;38:408–21

**PCR-RFLP-detected human papilloma virus infection in a group of Senegalese women attending an STD clinic and identification of a new HPV-68 subtype.**

G ASTORI, A BELTRAME, C PIPAN *et al.* *Intervirology* 1999;42:247–51

**Detection of human papilloma virus genomes by the primed in situ (PRINS) labelling technique.**

M RAMAEL, H VANSTEELENDT, G STUYVEN *et al.* *Path Res Practice* 1999;195:801–8

**DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro.**

K MATSUMOTO, K KAWANA, H YOSHIKAWA *et al.* *J Med Virol* 2000;60:200–4

**Capture ELISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in patients with anogenital warts.**

SW PENG, YM QI, N CHRISTENSEN *et al.* *Pathology* 1999;31:418–24

**Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcription derived from integrated papillomavirus oncogenes.**

R KLAES, SM WOERNER, R RIDDER *et al.* *Cancer Res* 1999;59:6132–6



**Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.**

K ZUMBACH, F KISSELJOV, O SACHAROVA *et al.* *Int J Cancer* 2000;85:313–8

**HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblasts LM cells.**

PJ DUERKSENHUGHES, J YANG, SB SCHWARTZ. *Virology* 1999;264:55–65

**CD4(+) tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7.**

H HOHN, H PILCH, S GUNZEL *et al.* *J Immunol* 1999;163:5715–22

**The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300.**

D PATEL, SM HUANG, LA BAGLIA, DJ MCCANCE. *EMBO J* 1999;18:5061–72

**The human papillomavirus type 16 E5 protein modulates phospholipase C- $\gamma$ -1 activity and phosphatidylinositol turnover in mouse fibroblasts.**

K CRUSIOS, M KASZKIN, V KINZEL, A ALONSO. *Oncogene* 1999;18:6714–8

**Interaction between the HPV-16 E2 transcriptional activator and p53.**

P MASSIMI, D PIM, C BERTOLI *et al.* *Oncogene* 1999;18:7748–54

**The E8/E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes.**

F STUBENRAUCH, M HUMMEL, T IFYNER, LA LAIMINS. *J Virol* 2000;74:1178–99

**The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element.**

MK OCONNOR, W STUNKEL, CH KOH *et al.* *J Virol* 2000;74:401–10

## Cervical cytology and colposcopy

**Cervical cytology after 2000: where to go?**

CJLM MEIJER, JMM WALBOOMERS. *J Clin Pathol* 2000;53:41–3

**Comparative evaluation of seven cell collection devices for cervical smears.**

PD KOHLBERGER, J STANI, G GITSCH *et al.* *Acta Cytol* 1999;43:1023–26

**Efficacy of cervical smear collection devices: a systemic review and meta-analysis.**

P MARTINHIRSCH, R LILFORD, G JARVIS, HC KITCHENER. *Lancet* 1999;354:1763–70

**Detection of false-negative Papanicolaou smears by rapid rescreening in a large routine cervical cytology laboratory.**

RG WRIGHT, JA HALFORD, EJ DITCHMAN. *Pathology* 1999;31:379–81

**Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models.**

S CATO, G MATUNAGA, I TRUJI *et al.* *Acta Cytol* 1999;43:1006–14

**A prototype computer image-based Papanicolaou smear proficiency test.**

RN TAYLOR, M GAGNON, J LANGE, T LEE *et al.* *Acta Cytol* 1999;43:1045–51

**The diagnostic value of computer-assisted primary cervical smear screening: a longitudinal cohort study.**

H DOORNEWAARD, YT VANDERSCHOUW, Y VANDERGRAAF *et al.* *Mod Pathol* 1999;12:995–1000

**Detection of human herpesvirus 8 in cervical cells of Chinese women with abnormal Papanicolaou smears.**

PKS CHAN, WH KI, MYM CHAN, AFB CHENG. *Clin Infect Dis* 1999;29:1584–5

**A study of the follow up patterns of women treated for CIN 2 and 3 before and after the introduction of the 1992 guidelines.**

CH MANN, S KEHOE, A BROWN, CM LUESLEY. *Br J Obstet Gynaecol* 1999;106:1126–9

**Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).**

R SNOECK, JC NOEL, C MULLER *et al.* *J Med Virol* 2000;60:205–9

**Effects of chemotherapy and tamoxifen on cervical and vaginal smears in bone marrow transplant recipients.**

K LIU, J MARSHALL, HS SHAW *et al.* *Acta Cytol* 1999;43:1027–33

**Serum carotenoids and vitamins and risk of cervical dysplasia from a case-control study in Japan.**

C NAGATA, H SHIMIZU, H YOSHIKAWA *et al.* *Br J Cancer* 1999;81:1234–7

**Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial.**

M MAIMAN, DH WATTS, J ANDERSEN *et al.* *Obstet Gynecol* 1999;94:954–61

**Preclinical feasibility study of NMP179, a nuclear matrix protein marker for cervical dysplasia.**

SK KEESEE, JL MEYER, ML HUTCHINSON *et al.* *Acta Cytol* 1999;43:1015–22

**Fhit alterations in cancerous and non-cancerous cervical epithelium.**

K YOSHINO, T ENOMOTO, T NAKAMURA *et al.* *Int J Cancer* 2000;85:6–13

## Other sexually transmitted infections

**A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya.**

IM MALONZA, MW TYNDALL, JO NDINYAACHOLA *et al.* *J Infect Dis* 1999;180:188693

**Cytotoxic distending toxin of *Haemophilus ducreyi* induces apoptotic death of Jurkat T cells.**

V GELFANOVA, EJ HANSEN, SM SPINOLA. *Infect Immun* 1999;67:6394–6408

## Public health and social aspects

**Encouraging use of coupons to stimulate condom purchase.**

DW DAHL, GJ GORN, CB WEINBERG. *Am J Public Health* 1999;89:1866–8

## Microbiology and immunology

**Human herpesvirus 8 cellular immune responses in homosexual men.**

HD STRICKLER, JJ GOEDERT, FR BETHKE *et al.* *J Infect Dis* 1999;180:1682–5

**Correlation of behaviours with microbiological changes in vaginal flora.**

JR SCHWEBKE, CM RICHEY, HL WEISS. *J Infect Dis* 1999;180:1632–6

**The identification of vaginal *Lactobacillus* species and the demographic and microbiologic characteristics of women colonized by these species.**

MAD ANTONIO, SE HAWES, SL HILLIER. *J Infect Dis* 1999;180:1950–6

**Common mucosal immunity: a novel hypothesis.**

FA MOORE. *Ann Surg* 2000;231:9–10

**Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle.**

FX LU, ZM MA, T ROURKE *et al.* *Infect Immun* 1999;67:6321–40

**Evaluation of the bacterial flora of the prostate using a 16s rRNA gene based polymerase chain reaction.**

WW HOCHREITER, JL DUNCAN, AJ SCHAEFFER. *J Urol* 2000;163:127–30

## Dermatology

**Incidence of preputial lichen sclerosus in adults: histologic study of circumcision specimens.**

O AYNAUD, D PIRON, JM CASANOVA. *J Am Acad Dermatol* 1999;41:923–6

**Penile cancer among patients with genital lichen sclerosus.**

MR NASCA, D INNOCENZI, G MICALI *et al.* *J Am Acad Dermatol* 1999;41:911–4

**Vulvar lichen sclerosus: an immunologic study.**

F SCRIMIN, S RUSTJA, R RADILLO *et al.* *Obstet-Gynecol* 2000;**95**:147–50

**Guidelines for management of Bowen's disease.**

NH COX, DJ EEDY, CA MORTON. *Br J Dermatol* 1999;**141**:633–41

**Vulvar melanoma, biologically different from other cutaneous melanomas.**

CJ DUNTON, D BERD. *Lancet* 1999;**354**:2013

**Cytomegalovirus balanitis in a renal transplant recipient.**

A RODRIGUEZ, B HILL, R GOPOLAN, GN SKLAR. *J Urol* 1999;**162**:2086

**The imidazoquinolines, imiquimod and R-848 induce functional but not phenotypic systemic vasculitis.**

RP BURNS, B FERBEL, M TOMAI *et al.* *Clin Immunol* 2000;**94**:13–23

---

## Miscellaneous

---

**The staying power of sexually transmitted diseases.**

W CATES, G DALLABETTA. *Lancet* 1999;**354**:62

**Breaking the silence surrounding rape.**

S RAMSAY. *Lancet* 1999;**354**:2018

**Seasonal variations in sexual activity and their implications for sexual health promotion.**

K WELLINGS, W MACDOWALL, M CATCHPOLE, J GOODRICH. *J Roy Soc Med* 1999;**92**:60–4

**Future change in sexual behaviour?**

CE WOOD. *Med J Aust* 1999;**171**:662–5

**Symptoms of reproductive-tract infection—not all that they seem to be.**

K TROLLOPEKUMAR. *Lancet* 1999;**354**:1745

**Reproductive-tract infections in women in low-income, low prevalence situation: assessment of syndromic management in Matlab, Bangladesh.**

S HAWKES, L MORISON, S FOSTER *et al.* *Lancet* 1999;**354**:1776–81

**High prevalence and incidence of sexually transmitted diseases in urban adolescent females despite moderate risk behaviors.**

RE BUNNELL, L HAHLEBERG, R ROLFS *et al.* *J Infect Dis* 1999;**180**:1624–31

**Sexual and reproductive health: what about boys and men: Education and service provision are the keys to increasing involvement.**

G YAMEY. *BMJ* 1999;**319**:1315

**Male adolescents and physician sex preference.**

CJ VANNESS, DA LYNCH. *Arch Pediat Adolesc Med* 2000;**154**:49–54

**Repeated school-based screening for sexually transmitted diseases: a feasible strategy for reaching adolescents.**

DA COHEN, M NSUAMI, DH MARTIN, TA FARLEY. *Pediatrics* 1999;**104**:1281–5

**Lesbians' sexual history with men: implications for taking a sexual history.**

AL DIAMANT, MA SCHUSTER, K MCGUIGAN, J LEVER. *Arch Intern Med* 1999;**159**:2730–8

**Hysterectomy and sexual function.**

JC RHODES, KH KJERULFF, RW LANGENBERG, GM GUZINSKI. *JAMA* 1999;**282**:1934–41

**Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections.**

TM HOOTON, AE STAPLETON, PL ROBERTS *et al.* *Clin Infect Dis* 1999;**29**:1600–1

**Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials.**

DA GRIMES, KF SCHULZ. *Contraception* 1999;**60**:57–64

**Genital pain without urogenital pathology: the koro-like syndrome.**

JM CABALLERO, A AVILA, X CARDONA *et al.* *J Urol* 2000;**163**:243

**Neurochemical characterization of the vestibular nerves in women with vulvar vestibulitis syndrome.**

N BOHMSTARKE, M HILLIGES, C FALCONER, E RYLANDER. *Gynecol Obstet Invest* 1999;**48**:270–5

**Acupuncture for vulvodinia.**

J POWELL, F WOJNAROWSKA. *J Roy Soc Med* 1999;**92**:579–81

**Pudendal nerve injury associated with avid bicycling.**

VS RICCHIUTI, CA HAAS, AD SEFTTEL *et al.* *J Urol* 1999;**162**:2099

**Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study.**

LD TRUE, RE BERGER, I ROTHMAN *et al.* *J Urol* 1999;**162**:2014–8

**Asthma and epididymitis: the calm before the storm.**

GHM GEORGE, JS AXFORD. *Ann Rheum Dis* 1999;**58**:731–6

**Male impotence.**

A MORGENTALER. *Lancet* 1999;**354**:1713–8

**Lack of diagnostic tools to prove erectile dysfunction: consequences for reimbursement?**

K LEHMANN, R EICHLISBERGER, TC GASSER. *J Urol* 2000;**163**:91–4

**Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.**

CG MCMAHON, R SAMALI, H JOHNSON. *J Urol* 1999;**162**:1992–6

**Tamoxifen versus placebo in the treatment of Peyronie's disease.**

C TELOKEN, EL RHODEN, TM GRAZZIOTIN *et al.* *J Urol* 1999;**162**:2003–5

**Iontophoresis for treatment of Peyronie's disease.**

CR RIEDL, E PLAS, P ENGELHARDT *et al.* *J Urol* 2000;**163**:95–9

**Behçet's syndrome: a multidisciplinary approach to clinical care.**

AJ WHALLETT, G THURAIRAJAN, J HAMBURGER *et al.* *Q J Med* 1999;**92**:727–40

**Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease?**

M SCHIRMER, KT CALAMIA, JD ODUFFY. *J Rheumatol* 1999;**26**:2511–2

**Secondary inflammation of the appendix via the vagina.**

SA BUTLERMANUEL, PT TOWNSEND. *J Roy Soc Med* 1999;**92**:465

**Two forms of reactive arthritis?**

P TOIVANEN, A TOIVANEN. *Ann Rheum Dis* 1999;**58**:737–41

**Reactive or infectious arthritis.**

JG KULPERS, L KOHLER, H ZEIDLER. *Ann Rheum Dis* 1999;**58**:661–4

**Beaver fever—a rare cause of reactive arthritis.**

M TUPCHONG, A SIMOR, C DEWAR. *J Rheumatol* 1999;**26**:2701–2